Literature DB >> 3501501

2'-Deoxycoformycin (Pentostatin) in hairy cell leukemia: response in patients refractory to interferon alpha.

A D Ho1, R Kuse, O Prümmer, F Porzsolt, W Hunstein.   

Abstract

Three patients with advanced hairy cell leukemia received low-dose deoxycoformycin treatment after failure to respond to therapy with interferon alpha. Patients 1 and 2 had progressive disease after splenectomy and subsequent treatment with recombinant interferon alpha (for 7 and 3 months, respectively). DCF was administered at 4 mg/m2 weekly for 3 weeks, and then once every week for 6 weeks. Patient 1 was in complete remission after 9 weeks of treatment and patient 2 in partial remission with normalization of peripheral blood counts. The third patient, also splenectomized, developed hepatotoxicity after therapy trial with interferon for 24 days and no objective improvement was observed at this stage. She subsequently responded to DCF treatment with improvements in blood counts and bone marrow. This report demonstrates that DCF is highly effective in hairy cell leukemia and non-cross-resistant with interferon alpha.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501501     DOI: 10.1007/BF01717832

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  15 in total

1.  Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms.

Authors:  A S Spiers; J C Ruckdeschel; J Horton
Journal:  Scand J Haematol       Date:  1984-02

2.  Enzymes of purine metabolism in hairy cell leukemia.

Authors:  A D Ho; G Dietz; I Trede; R Schwartz; A V Hoffbrand; W Hunstein
Journal:  Cancer       Date:  1986-07-01       Impact factor: 6.860

3.  Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function.

Authors:  E W Gelfand; J J Lee; H M Dosch
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

4.  Treatment of hairy cell leukemia with recombinant alpha 2 interferon.

Authors:  M J Ratain; H M Golomb; J W Vardiman; E E Vokes; R H Jacobs; K Daly
Journal:  Blood       Date:  1985-03       Impact factor: 22.113

5.  The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy.

Authors:  M R Grever; M F Siaw; W F Jacob; J A Neidhart; J S Miser; M S Coleman; J J Hutton; S P Balcerzak
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

6.  Association of severe and fatal infections and treatment with pentostatin.

Authors:  P J O'Dwyer; A S Spiers; S Marsoni
Journal:  Cancer Treat Rep       Date:  1986-09

7.  Response to 2'-deoxycoformycin after failure of interferon-alpha in nonsplenectomized patients with hairy cell leukemia.

Authors:  K A Foon; G M Nakano; C A Koller; D L Longo; R G Steis
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

8.  Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results.

Authors:  K A Foon; A E Maluish; P G Abrams; S Wrightington; H C Stevenson; A Alarif; M F Fer; W R Overton; M Poole; E F Schnipper
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

9.  Low-dose deoxycoformycin in lymphoid malignancy.

Authors:  M R Grever; J M Leiby; E H Kraut; H E Wilson; J A Neidhart; R L Wall; S P Balcerzak
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

10.  Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).

Authors:  A S Spiers; D Moore; P A Cassileth; D P Harrington; F J Cummings; R S Neiman; J M Bennett; M J O'Connell
Journal:  N Engl J Med       Date:  1987-04-02       Impact factor: 91.245

View more
  1 in total

Review 1.  Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.

Authors:  A D Ho; K Ganeshaguru
Journal:  Klin Wochenschr       Date:  1988-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.